Revolution Medicines’ daraxonrasib, a KRAS-focused oral therapy, delivered a survival benefit in a Phase 3 pancreatic cancer readout highlighted by STAT+. In advanced pancreatic adenocarcinoma, patients treated with the daily pill had a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy. The company is using the results to pursue FDA approval, and the transcript with NYU Langone’s Paul Oberstein—an investigator in the trial—frames the dataset as potentially opening a new treatment era for a mutation historically hard to drug. The broader field is also seeing renewed clinical activity around next-generation KRAS inhibitors following early durability disappointments. For biotech stakeholders, the readout tightens the link between targeted RAS biology and measurable outcomes in a disease area where incremental gains have often failed to hold up long-term, raising the urgency for follow-on trial strategies and biomarker-driven patient selection.